Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment‐Naive Subjects with HIV‐1 Infection

This publication has 30 references indexed in Scilit:

• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
  The Lancet, 2008
• Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy
  AIDS, 2008
• Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands
  Virology, 2007
• Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults
  AIDS, 2007
• Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry
  Journal of Virology, 2007
• Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism
  Antimicrobial Agents and Chemotherapy, 2007
• HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
  Virology, 2006
• Insulin Resistance and Diabetes Mellitus in HIV-Infected Patients Receiving Antiretroviral Therapy
  Metabolic Syndrome and Related Disorders, 2004
• Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review
  Scandinavian Journal of Infectious Diseases, 2004
• Conversion Rate towards a Syncytium‐Inducing (SI) Phenotype during Different Stages of Human Immunodeficiency Virus Type 1 Infection and Prognostic Value of SI Phenotype for Survival after AIDS Diagnosis
  The Journal of Infectious Diseases, 1999